tbuckley/cabot-search huggingface dataset:
Adjuvant management of male breast cancer in Bulgaria
Authors: A.A. Konsoulova-Kirova, A. Yordanov, D. Kostova-Lefterova, S. El Shemeri, M. Dimova, S.A. Strashilov, R.H. Hristova, S.I. Maslyankov, Y. Marincheva, M.B. Vasileva
Journal: Annals of Oncology (2019)

Background: As a rare disease, knowledge about management of male breast cancer (male BC) is scarce but increasing in the last years. Still, according to RARECAREnet study, 5-year relative survival in Bulgarian male BC patients is 18% less than European mean. We look for potential reasons for this low survival rate; we also identify trends or gaps in the adjuvant (ADJ) management. Analysis of available data would lead to perception of the lack of knowledge about management of MBC and would identify areas for future improvement. Methods: This is a retrospective population based study of all patients with male BC, diagnosed between 2002 and 2013 in Bulgaria. Clinicopathological features and treatment was obtained from the National Cancer Registry. We compare ADJ management in 2 time intervals: 2002-2007 and 2008-2013. Results: Data about the clinicopathological features of the patients with male BC are shown in Table. Indications for ADJ endocrine treatment (ET), chemotherapy (CHT) or radiotherapy (RT) were considered as per extrapolation for females with BC (Table). Clinicopathological features of patients with male BC, divided in two time intervals. For 2002-2007: Of all 70 nonmetastatic HR+ patients, 10 (14.3%) had ADJ ET; For 2008-2013: Of all 96 nonmetastatic HR+ patients, 36 had ADJ ET (37.5%). For 2002-2007: ADJ RT was delivered to 12 patients of all 70 N+ nonmetastatic male BC (17.1%) For 2008-2013: ADJ RT was delivered to 63 patients of all 94 N+ nonmetastatic male BC (67%) We consider that at least patients with HER+ male BC as well as stages T2-4N+M0 would be indicated for ADJ CHT (73 and 123 for both periods) whereas ADJ CHT was administered to only 9 and 48 patients respectively (12.3 and 39% respectively). Conclusions: Despite the recommendations to treat male BC as BC in females, use of ADJ modalities, incl. ET, CHT or RT are still largely underused in male BC. There is though a clear trend towards improvement with the years. Data quality of reported cases is improving over time, as well as the staging, diagnosis and ADJ treatment. Despite this, In Bulgaria they remain largely suboptimal and improvement is urgently needed. Legal entity responsible for the study: Assia Konsoulova. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Table98PTimeAll ptsPts with known HRHR+ AnyTN,M0known HER2HER2+T2-4 N+M0known NAnyT, N+ M02002-200724311870501558193702008-201327815696133398423994 Open table in a new tab
Sugar-Sweetened Beverage Taxes
Authors: Kristine A. Madsen, James Krieger, Xavier Morales
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POST-COLONOSCOPY COMPLICATIONS WITHIN THE COLORECTAL CANCER SCREENING PROGRAMS OF THE VENETO REGION (ITALY)
Authors: M Zorzi, C Hassan, L Benazzato, A Fantin, C Fedato, S Guzzinati
Journal: Endoscopy (2019)

To define the complication rate and the 30-days mortality rate after colonoscopy within the colorectal cancer screening programs of the Veneto Region (North East of Italy) and to identify the variables associated with complications.
High diversity of invasive Haemophilus influenzae isolates in France and the emergence of resistance to third generation cephalosporins by alteration of ftsI gene
Authors: Ala-Eddine Deghmane, Eva Hong, Sara Chehboub, Aude Terrade, Michaël Falguières, Morgan Sort, Odile Harrison, Keith A. Jolley, Muhamed-Kheir Taha
Journal: Journal of Infection (2019)
Modifying the Organ Matrix Pre-engraftment: A New Transplant Paradigm?
Authors: Jordan R. Yaron, Jacek M. Kwiecien, Liqiang Zhang, Sriram Ambadapadi, Dara N. Wakefield, William L. Clapp, Wojciech Dabrowski, Michelle Burgin, Barbara H. Munk, Grant McFadden, Hao Chen, Alexandra R. Lucas
Journal: Trends in Molecular Medicine (2019)
THE FIRST EXPERIENCE OF CHOLEDOCHOSCOPY USING SPYGLASS SYSTEM IN THE REPUBLIC OF BELARUS
Authors: N Lahodzich, A Varabei, Y Butra, A Kapran
Journal: Endoscopy (2019)

For the period from March 2017 to September 2018 in the Republican Center for Reconstructive Surgical Gastroenterology and Coloproctology, 15 choledochoscopies were performed in 15 patients aged 48 – 82 years (mean age 64.2). There were 3 men, 12 women. The indications for choledochoscopy were: suspicion of a neoplastic process – 3 patients; stones of bile duct with large size (more 20 mm) – 8 patients; suspected stones – 4 patients. The study was performed in an X-ray room or operating room using the SpyGlass endoscopic system of the Boston Scientific trademark. Laser lithotripsy was performed using laser setup with a 1440nm optical fiber with a power of 10 – 12 W.
CLINICAL PERFORMANCE OF NEW THREE POINTS 19 G ENDOSCOPIC ULTRASOUND CORE NEEDLE FOR THE HISTOLOGICAL DIAGNOSIS OF MESENCHYMAL TUMORS
Authors: G Delconte, F Cavalcoli, P Collini, S Pasquali, A Magarotto, E Masci
Journal: Endoscopy (2019)

Different type and size of histological needles for endoscopic ultrasound guided fine needle biopsies (EUS-FNB) have been developed, however their best application has to be defined. The diagnosis of mesenchymal tumors (MT) often requires tissue for molecular studies (i.e. ISH. FISH, NGS) beside H&E and immunohistochemistry. Aim of the study was to evaluate the clinical performance of a new three-points 19 G core needle in MT.
ENDOSCOPIC ULTRASOUND-GUIDED RENDEZVOUS IN BENIGN BILIARY OR PANCREATIC DISORDERS WITH A 22-GAUGE NEEDLE AND A 0.018-INCH NOVAGOLD GUIDEWIRE
Authors: B Martínez, J Martínez, C Mangas-San Juan, M Bozhychko, JA Casellas, J Ramón Aparicio
Journal: Endoscopy (2019)

To assess the efficacy and safety of endoscopic ultrasound-guided rendezvous (EUS-RV) for benign biliary or pancreatic disorders with a 22-gauge needle and a 0.018-inch guidewire.
ANALYSIS OF GASTRIC AND DUODENAL BIOPSY RESULTS IN PATIENTS PRESENTING WITH DYSPEPSIA: A CROSS SECTIONAL STUDY IN A TERTIARY HOSPITAL CENTER IN LEBANON
Authors: S Farhat, M Hussein Kamareddine, N Bou-Ayash, Y Ghosn, G Jabbour, G Cortas, S Khoury, K Bedran
Journal: Endoscopy (2019)

Around a half a century ago, Peleyo Correa described a "Model for Gastric Cancer Development" referred to as Correa's cascade. Today, roughly half of the world's population are infected with Helicobacter pylori (H. pylori), the main cause of chronic gastritis. While the reversibility of Correa's cascade is still debatable, there is insufficient data on the specific stage of the cascade during which H. pylori is detected and treated and its effect on prognosis.
CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis
Authors: Xiao-Lu Ma, Min-Na Shen, Bo Hu, Bei-Li Wang, Wen-Jing Yang, Li-Hua Lv, Hao Wang, Yan Zhou, An-Li Jin, Yun-Fan Sun, Chuan-Yan Zhang, Shuang-Jian Qiu, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo
Journal: Journal of Hematology & Oncology (2019)

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence. Accumulating evidence shows that CD73-expressing tumor cell is implicated in development of several types of cancer. However, the role of CD73 in HCC cell has not been systematically investigated and its underlying mechanism remains elusive. CD73 expression in HCC cell was determined by RT-PCR, Western blot, and immunohistochemistry staining. Clinical significance of CD73 was evaluated by Cox regression analysis. Cell counting kit-8 and colony formation assays were used for proliferation evaluation. Transwell assays were used for motility evaluations. Co-immunoprecipitation, cytosolic and plasma membrane fractionation separation, and ELISA were applied for evaluating membrane localization of P110β and its catalytic activity. NOD/SCID/γc(null) (NOG) mice model was used to investigate the in vivo functions of CD73. In the present study, we demonstrate that CD73 was crucial for epithelial-mesenchymal transition (EMT), progression and metastasis in HCC. CD73 expression is increased in HCC cells and correlated with aggressive clinicopathological characteristics. Clinically, CD73 is identified as an independent poor prognostic indicator for both time to recurrence and overall survival. CD73 knockdown dramatically inhibits HCC cells proliferation, migration, invasion, and EMT in vitro and hinders tumor growth and metastasis in vivo. Opposite results could be observed when CD73 is overexpressed. Mechanistically, adenosine produced by CD73 binds to adenosine A2A receptor (A2AR) and activates Rap1, which recruits P110β to the plasma membrane and triggers PIP3 production, thereby promoting AKT phosphorylation in HCC cells. Notably, a combination of anti-CD73 and anti-A2AR achieves synergistic depression effects on HCC growth and metastasis than single agent alone. CD73 promotes progression and metastasis through activating PI3K/AKT signaling, indicating a novel prognostic biomarker for HCC. Our data demonstrate the importance of CD73 in HCC in addition to its immunosuppressive functions and revealed that co-targeting CD73 and A2AR strategy may be a promising novel therapeutic strategy for future HCC management.
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
Authors: Aaron J Franke, William Paul Skelton, Jason S Starr, Hiral Parekh, James J Lee, Michael J Overman, Carmen Allegra, Thomas J George
Journal: JNCI Journal of the National Cancer Institute (2019)

Abstract Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United States. Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair–deficient (dMMR) tumors. Recent studies in the refractory CRC setting have led to US Food and Drug Administration approvals for pembrolizumab as well as nivolumab (with or without ipilimumab) for tumors harboring an MSI-H:dMMR molecular profile. Several randomized controlled trials are underway to move immunotherapy into the frontline for metastatic cancer (with or without chemotherapy) and the adjuvant setting. Awareness of these studies is critical given the relatively low incidence (approximately 3%–5%) of MSI-H:dMMR in advanced or metastatic CRC to support study completion, because the results could be potentially practice changing. The real challenge in this disease is related to demonstrating the benefit of immunotherapy for the vast majority of patients with CRC not harboring MSI-H:dMMR. Given the rapid pace of scientific changes, this article provides a narrative review regarding the current landscape of immunotherapy for CRC. Particular attention is paid to the currently available data that inform today’s clinical practice along with upcoming randomized controlled trials that may soon dramatically change the treatment landscape for CRC.
Abstract 4606: An in vitro and in vivo evaluation of novel anticancer agents in a triple negative breast cancer model
Authors: Tamorah Hawthorne, Joseph Gallien, Lee Gibbs, Janeque Jones, Shannon Muir, Lyndsay V. Rhodes, Jennifer Driver, Hafez Khalili, Matthew Burow, KiTani A. Parker-Johnson
Journal: Cancer Research (2010)

Abstract Patients diagnosed with triple negative breast cancer, which is the absence of the estrogen (ER), progesterone (PR), and Her2/neu receptor have a poor prognosis and there is a critical need to develop novel antineoplastic agents for this breast cancer sub-type. Therefore, the focus of this project is to identify novel anticancer agents with in vitro and in vivo antiproliferative activity in a triple negative breast cancer model. Previously, our laboratory synthesized a group of novel isochalcones called DJ compounds that demonstrated significant in vitro antiproliferative effects. Cell proliferation of MDA-MB-231 cells was measured using the alamar blue dye method and produced IC50 values of DJ52, DJ56, and DJ82 at 10−6M, 10−5M, and 10−5M, respectively. Binding studies have indicated that these agents do not bind the ER but appear to inhibit a phosphorylation step in the epidermal growth factor (EGFR) receptor pathway. In vivo studies were also conducted by implanting tumors derived from MDA-MB231 cells into SCID mice to determine tumor regression was measured over 20 days. DJ52 at 50mg/kg caused significant decrease (p value &amp;lt;.05) decreased tumor volume by nearly fifty percent compared to the control with vehicle alone. Therefore, these data suggests that DJ52 has merit for further evaluation for potential intervention in patients diagnosed with triple negative breast cancer. Our laboratory continues our efforts to understand the mechanism of action of these agents to potentially provide alternative pharmacological options for these patients for better health outcomes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4606.
Peut-on prévoir la survenue de chute d'escarre post ligature des varices oesophagiennes (LVO)?
Authors: R Benjira, O Laalj, M Lahlali, A Lamine, H Abid, N Lahmidani, M Elyoussfi, N Aqodad, DA Benajah, SA Ibrahimi, M Elabkari
Journal: Endoscopy (2019)

La ligature endoscopique (LVO) est le traitement de choix de l'hémorragie variqueuse chez le patient cirrhotique. La chute d'escarre, en demeure une complication rare mais grave.
LONG-TERM EFFICACY AND COST EFFECTIVENESS OF ENDOSCOPIC TREATMENT OF PANCREATIC PSEUDOCYSTS: PIGTAIL VS SELF EXPANDING METAL STENTS (SEMS)
Authors: E Dieninyte-Misiune, J Stanaitis, J Valantinas
Journal: Endoscopy (2019)

Currently endoscopic therapy is a gold standard management option of pancreatic pseudocysts. However, particular type of stent application in larger pseudocysts is still debated, especially regarding long-term outcomes and costs. Therefore, we hypothesized that due to its larger diameter and improved drainage SEMS would be as efficacious and cost effective as pigtail stents in resolving pseudocysts larger than 6 cm.
Mental health research is losing £1.5bn funding over 10 years, says charity
Authors: Gareth Iacobucci
Journal: BMJ (2019)

A mental health charity has launched legal action against the UK government’s largest medical research funder to challenge the way it allocates funds.

Miricyl, which campaigns for increased government funding for mental illness research, argues that the way UK Research and Innovation allocates funding discriminates against mental health. It estimates that mental health researchers may lose up to £1.5bn of funding over the next 10 years because of the methods UKRI uses to distribute research grants.

It argues that research funding should be awarded according to an illness’s human and financial effects on society.

The non-departmental body UKRI …
Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake
Authors: Kevin D. Hall, Alexis Ayuketah, Robert Brychta, Hongyi Cai, Thomas Cassimatis, Kong Y. Chen, Stephanie T. Chung, Elise Costa, Amber Courville, Valerie Darcey, Laura A. Fletcher, Ciaran G. Forde, Ahmed M. Gharib, Juen Guo, Rebecca Howard, Paule V. Joseph, Suzanne McGehee, Ronald Ouwerkerk, Klaudia Raisinger, Irene Rozga, Michael Stagliano, Mary Walter, Peter J. Walter, Shanna Yang, Megan Zhou
Journal: Cell Metabolism (2019)
Chimeric antigen receptor T (CAR‐T) cells present with reactive and pleomorphic morphology in bone marrow
Authors: Xueying Han, Chen Wang, Jin Zhou
Journal: American Journal of Hematology (2019)

A 25-year-old male patient with relapsed B-cell acute lymphoblastic leukemia was treated with chimeric antigen receptor T (CAR-T) cell therapy as part of a phase 1/2 trial. He received a dose of 2 × 108 autologous CAR-T cells that were prepared with a lentivirus vector coding for T cell signaling and costimulatory domains specifically directed against CD19. Following CAR-T cell infusion, bone marrow exam was performed periodically, and the marrow aspirate showed a decrease in leukemic blasts, along with emerging CAR-T cells that appeared as pleomorphic and reactive lymphocytes. Some large multinucleated forms and mitoses were present (Image 1). CAR-T cells were confirmed by immunostaining for CAR-T specific markers and included CD4 + and CD8 + T-cells. CAR-T cells were prominent in the bone marrow between day 7 and 21, then decreased while normal hematopoietic cells were recovered. The patient achieved complete remission and was monitored in follow-up. CAR-T immunotherapy is increasingly used in treating hematological malignancies.1-3 It becomes relevant to recognize these cells in assessing bone marrow. Lymphocyte activation is accompanied by morphological changes. Reactive lymphocytes are typically seen in viral infections, referred to as atypical lymphocytes. CAR-T cells are expected to undergo intense and remarkable activation for their tumor killing. It is noteworthy that morphologically, CAR-T cells may resemble large lymphoma cells. The dramatic changes in morphology likely reflect the intensity of undergoing reactive and proliferative activities of CAR-T cells.
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)
Authors: Philippe Moreau, Shaji Kumar, Ralph Boccia, Shinsuke Iida, Hartmut Goldschmidt, Kim Cocks, Andrew Trigg, Anita Zahlten-Kumeli, Emre Yucel, Sumeet S. Panjabi, Meletios Dimopoulos
Journal: Leukemia (2019)

We compared patient-reported outcomes (PROs) with once-weekly carfilzomib 70 mg/m2 (Kd70 mg/m2) vs. twice-weekly carfilzomib 27 mg/m2 (Kd27 mg/m2) plus dexamethasone in relapsed or refractory multiple myeloma (RRMM). Patient-reported convenience/satisfaction collected at Cycle 2, Day 1 was compared between groups using logistic regression. European Organization for Research and Treatment of Cancer QOL Questionnaire (QLQ-C30), MM-module (QLQ-MY20), and EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaires were administered at baseline, then every other cycle. PROs were compared between groups using mixed models for repeated measures. Times from randomization to first deterioration (TTD) in scores were analyzed using Cox regression. PRO analyses included 469 patients. Once-weekly Kd70 mg/m2 patients reported greater convenience (odds ratio [OR], 4.98; p < 0.001) and satisfaction (OR, 2.41; p = 0.059) vs. twice-weekly Kd27 mg/m2. The mixed models for repeated measures demonstrated no clinically meaningful differences in scores between treatment arms. Clinically meaningful deterioration in QLQ-C30 Global Health Status/QOL rates were 34.2% (once-weekly Kd70 mg/m2) vs. 40.3% (twice-weekly Kd27 mg/m2). TTD was longer for once-weekly Kd70 mg/m2 vs. twice-weekly Kd27 mg/m2 for QLQ-C30 fatigue (HR, 0.79; p = 0.035), QLQ-MY20 disease symptoms (HR, 0.67; p = 0.008), EQ-5D-5L index score (HR, 0.58; p = 0.002), and EQ-5D-5L Visual Analog Scale (HR, 0.75, p = 0.031). Once-weekly Kd70 mg/m2 improved convenience/satisfaction, and reduced HRQOL deterioration vs. twice-weekly Kd27 mg/m2, supporting convenient, once-weekly Kd70 mg/m2 dosing in RRMM.
Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction
Authors: Giovanni Benfari, Clemence Antoine, Wayne L. Miller, Prabin Thapa, Yan Topilsky, Andrea Rossi, Hector I. Michelena, Sorin Pislaru, Maurice Enriquez-Sarano
Journal: Circulation (2019)

Background: Functional tricuspid regurgitation (FTR) is common in heart failure with reduced ejection fraction and mostly consequent to pulmonary hypertension. However, the intrinsic clinical implications of FTR are not fully understood. Methods: The cohort of all Mayo Clinic patients from 2003 to 2011 diagnosed with heart failure stage B-C and ejection fraction&lt;50%, with FTR grading and systolic pulmonary artery pressure estimation by Doppler echocardiography was identified and outcomes were analyzed. Patients with pacemakers/defibrillators, organic valve disease, or previous valve surgery were excluded. The primary outcome measure was overall mortality (censored at implantation of a defibrillator, ventricular assist device, or cardiac transplantation), adjusting for clinical and echocardiographic associates with mortality and major comorbidities. Results: Among 13 026 patients meeting inclusion criteria, FTR was detected in 88% (N=11 507: 33% trivial, 32% mild, 17% moderate, and 6% severe), aged 68±14 years, 35% women, ejection fraction 36±10%, systolic pulmonary artery pressure 41±14 mm Hg with 20% atrial fibrillation. Covariates independently associated with FTR included elevated systolic pulmonary artery pressure, older age, female sex, lower ejection fraction, mitral regurgitation, and atrial fibrillation (all P &lt;0.0001). FTR was independently associated with more dyspnea, impaired kidney function, and lower cardiac output ( P &lt;0.003 for all). For long-term outcome, higher FTR degree compared with trivial tricuspid regurgitation was independently associated with higher mortality (adjusted hazard ratios 1.09 [1.01-1.17] for mild FTR, 1.21 [1.11-1.33] for moderate FTR and 1.57 [1.39-1.78] for severe FTR); hence, 5-year survival was substantially lower with increasing severity of functional FTR, 68±1% for trivial FTR, 58±2% for mild FTR, 45±2% for moderate FTR, and 34±4% for severe FTR. Conclusions: In this large cohort of patients with heart failure with reduced ejection fraction, FTR was common and independently associated with pulmonary hypertension, atrial fibrillation, and more severe heart failure presentation. Long-term, higher FTR severity is associated with considerably worse survival, independently of baseline characteristics. Given these untoward outcomes associated with FTR in patients with heart failure with reduced ejection fraction, clinical trials should be directed at testing FTR treatment.
Retrospective analysis of arteriovenous fistula patency and failure in patients on dialysis for end-stage kidney disease in the Gaza strip
Authors: Abdelrahman Alshaikh Ahmad, Mohammed Al.Qudairi, Abdulah Abo Jalambo, Mohammed Elser, Khalid Alnahhal, Khamis Elessi, Mohammed Kalloub
Journal: The Lancet (2019)